These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 36077816)
1. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Shimose S; Iwamoto H; Tanaka M; Niizeki T; Kajiwara M; Itano S; Moriyama E; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077816 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060 [TBL] [Abstract][Full Text] [Related]
3. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Miyazaki M; Ohkawa K; Mita E; Iio S; Nozaki Y; Yakushijin T; Imai Y; Kodama T; Hikita H; Tatsumi T; Takehara T Hepatol Res; 2022 Jul; 52(7):630-640. PubMed ID: 35417606 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359 [TBL] [Abstract][Full Text] [Related]
5. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. Takaki S; Kurosaki M; Mori N; Tsuji K; Ochi H; Marusawa H; Nakamura S; Tada T; Narita R; Uchida Y; Akahane T; Kondo M; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Ogawa C; Sato T; Tamaki N; Yasui Y; Tsuchiya K; Izumi N Invest New Drugs; 2023 Apr; 41(2):340-349. PubMed ID: 36995548 [TBL] [Abstract][Full Text] [Related]
6. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data. Shimose S; Sugimoto R; Hiraoka A; Tanaka M; Iwamoto H; Tanaka Y; Tada F; Ohama H; Niizeki T; Shirono T; Moriyama E; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T Hepatol Res; 2023 Feb; 53(2):116-126. PubMed ID: 36316794 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma. Kinami T; Uchikawa S; Kawaoka T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Oka S Cancer Med; 2024 Mar; 13(5):e7025. PubMed ID: 38477514 [TBL] [Abstract][Full Text] [Related]
8. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH; Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443 [TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118 [TBL] [Abstract][Full Text] [Related]
10. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y Cancer Med; 2023 Apr; 12(7):7772-7783. PubMed ID: 36518086 [TBL] [Abstract][Full Text] [Related]
11. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy. Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853 [TBL] [Abstract][Full Text] [Related]
12. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253 [TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Shimose S; Iwamoto H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Nakano M; Suga H; Kuromatsu R; Yamaguchi T; Kawaguchi T; Tanaka M; Noguchi K; Koga H; Torimura T Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664489 [TBL] [Abstract][Full Text] [Related]
14. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J; Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971 [TBL] [Abstract][Full Text] [Related]
15. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Iwamoto H; Shimose S; Noda Y; Shirono T; Niizeki T; Nakano M; Okamura S; Kamachi N; Suzuki H; Sakai M; Kajiwara A; Itano S; Tanaka M; Yamaguchi T; Kuromatsu R; Koga H; Torimura T; On Behalf Of The Kurume Liver Cancer Study Group Of Japan Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34205099 [TBL] [Abstract][Full Text] [Related]
16. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib. Chihiro K; Kawaoka T; Uchikawa S; Kinami T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Imamura M; Aikata H; Oka S Oncology; 2023; 101(8):491-501. PubMed ID: 37429266 [TBL] [Abstract][Full Text] [Related]
17. Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. Unome S; Imai K; Takai K; Miwa T; Hanai T; Nishigaki Y; Hayashi H; Kochi T; Shimizu S; Nagano J; Iritani S; Suetsugu A; Shimizu M Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551574 [TBL] [Abstract][Full Text] [Related]
18. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. Cabibbo G; Reig M; Celsa C; Torres F; Battaglia S; Enea M; Rizzo GEM; Petta S; Calvaruso V; Di Marco V; Craxì A; Singal AG; Bruix J; Cammà C Liver Cancer; 2022 Jan; 11(1):75-84. PubMed ID: 35222509 [TBL] [Abstract][Full Text] [Related]